TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers report that declining cardiolipin in muscle mitochondria is linked to changes in muscle fibers in aging and disease. Mouse experiments suggest the shift toward slow-twitch fibers can help protect muscle cells from mitochondrial stress, but whether targeting this process can treat age-related muscle loss in people is unknown.
Researchers report that a decline in cardiolipin, a fat molecule in mitochondria, may help explain why aging muscles shift toward slow-twitch fibers. Experiments in mice suggest this change is not only a sign of weakening: it may also protect muscle cells from stress, a finding that complicates ideas about how to treat age-related muscle loss.
The study examined cardiolipin, which helps maintain the inner membrane structure of mitochondria, the cell structures that produce much of the energy muscles use. The researchers found lower cardiolipin levels in muscle mitochondria from aging or diseased mice and humans, alongside structural abnormalities and reduced mitochondrial function. The supplied report does not identify the number of human samples or provide details of the study’s publication.
To test whether the drop could cause muscle changes, the team lowered cardiolipin in young mice. Their muscle fibers shifted away from fast-twitch fibers, which support powerful movements, and toward slow-twitch fibers, which are associated with sustained activity. The report says the shift resembled patterns seen in older mice and people. Restoring cardiolipin to about two-thirds of its normal concentration began reversing muscle wasting and prevented the premature deaths reported in the affected mice.
The researchers linked the fiber shift to increased reactive oxygen species (ROS) from damaged mitochondria. ROS can harm cell structures but also act as signals. In lab-grown muscle cells, reducing ROS with an antioxidant made the fiber transformation less pronounced; inhibiting the protein ERRγ stopped the transition entirely. In mice with low cardiolipin, muscles also took up more glucose, which tracing experiments indicated was redirected toward making antioxidants rather than primarily being used for energy.
A Protective Shift With a Cost
The findings suggest that some changes associated with aging muscle may serve as adaptations to mitochondrial stress, rather than simply reflecting a loss of function. The reported trade-off is between the power of fast-twitch fibers and the stress defenses supported by the slow-twitch shift. That could help explain why muscle tissue changes in response to aging or disease even as its energy-producing machinery becomes less effective.
The result also cautions against assuming that suppressing oxidative stress will necessarily help weakened muscle. In the mouse experiments described by the researchers, antioxidants that reduced ROS made outcomes worse, because ROS also appeared to trigger a protective response. This does not establish that antioxidants harm people with muscle loss, but it highlights why treatments based on the mechanism will need testing in humans.
Cardiolipin and ERRγ are possible research targets, not established treatments for ordinary age-related muscle decline. The study’s mouse results point to potential ways of influencing muscle adaptation, while the human findings in the report show only that cardiolipin levels decline with age or disease.
Popular right now
Dyson Cyclone V10 Origin Cordless Vacuum
Bose QuietComfort Wireless Bluetooth Headphones with Active Noise Cancellation, Mic, USB‑C Charging, Deep Bass, 24‑Hour Battery – White Smok
DeLonghi Rivelia Automatic Espresso Machine Bundle with Grinder and Frother, Beige
As an affiliate, we earn on qualifying purchases.
From Mitochondria to Muscle Fibers
Muscle contains different fiber types. Fast-twitch fibers produce rapid, forceful movement but fatigue relatively quickly. Slow-twitch fibers support sustained activity and contain more mitochondria. With age, muscle strength tends to decline and mitochondria can become less efficient; the greater share of slow-twitch fibers in aging muscle has therefore posed a biological puzzle.
The study’s proposed chain links lower cardiolipin to altered mitochondrial structure and function, increased ROS signaling, and activation of ERRγ, which helps coordinate changes in mitochondria and fiber characteristics. The researchers also report that remodeled muscle cells redirect more glucose toward producing antioxidants. These steps offer a possible explanation for the fiber shift, but they do not show that every case of age-related muscle weakness follows the same pathway.
The report notes that the U.S. Food and Drug Administration recently granted accelerated approval to elamipretide for Barth syndrome, a rare inherited disorder. The medicine is designed to stabilize cardiolipin. That approval indicates cardiolipin can be targeted medically in that condition; it is not evidence that elamipretide works for age-related muscle loss.
“The fiber switch is not the muscle failing, but the muscle trading power for protection.”
— Assistant Professor Fabian Finger, University of Copenhagen, first and co-corresponding author
Human Treatment Evidence Is Missing
The key limits are the gap between mouse experiments and human treatment and the scope of the human samples. According to the report, human muscle tissue was used to show that cardiolipin levels also decrease with age, but the protective mechanism and reversal of muscle wasting were demonstrated in mice. It is not clear from the supplied material how many people were studied or how their ages and health conditions were distributed.
The results do not show whether restoring cardiolipin or changing ERRγ activity would improve strength, mobility, or survival in people with typical age-related muscle loss. Nor do they establish which aspects of the observed response may be beneficial or harmful across different muscle-wasting conditions. The source material ends before completing a further quotation from a researcher, so no additional claim from that unfinished statement can be reported.
Testing Targets Beyond Mice
The next step is to determine whether the proposed pathway operates in people in ways that could be safely and meaningfully altered. Further research would need to test whether interventions that affect cardiolipin or ERRγ improve human muscle outcomes, and whether the protective fiber shift can be preserved without worsening weakness. The source material does not provide a timeline for such studies or identify a clinical trial for age-related muscle loss.
Elamipretide’s use for Barth syndrome does not by itself answer those questions: that approval concerns a specific inherited disorder, not age-related muscle decline. Until human studies test the approach for this purpose, the findings remain a proposed biological explanation and a direction for research, rather than a treatment recommendation.
Key Questions
What did the researchers find?
They linked lower cardiolipin in muscle mitochondria with changes in muscle fibers. Mouse and cell experiments suggest that the shift toward slow-twitch fibers may help protect cells under mitochondrial stress.
Does the study show that this process causes muscle weakness in people?
No. The report says human samples showed declining cardiolipin with age or disease, while tests of the protective mechanism and reversal of muscle wasting were conducted in mice. The human evidence described does not establish cause or treatment effect.
Why might a shift to slow-twitch fibers help?
The researchers propose that the shift is part of a response to mitochondrial stress. In their experiments, muscle cells redirected more glucose toward making antioxidants, which may help limit damage from elevated ROS.
Do the findings mean people should avoid antioxidants?
No. The reported result came from experiments in mice and lab-grown cells; it does not establish how antioxidant supplements affect people with muscle weakness. Decisions about supplements or treatment should be discussed with a qualified health professional.
Is elamipretide a treatment for age-related muscle loss?
The source reports accelerated FDA approval of elamipretide for Barth syndrome, a rare inherited disorder. It does not report approval or proven effectiveness for ordinary age-related muscle decline.
Source: sciencedaily.com
